Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal
Sangamo Therapeutics has secured a licensing deal with Eli Lilly that helps extend the cash-strapped company’s runway. Lilly will pay Sangamo $18 million upfront for the rights to use Sangamo’s neurotropic adeno-associated virus capsid to develop a genomic treatment for a central nervous system disease, Sangamo announced on April 3.
Sangamo Therapeutics has secured a licensing deal with Eli Lilly that helps extend the cash-strapped company’s runway. Lilly will pay Sangamo $18 million upfront for the rights to use Sangamo’s neurotropic adeno-associated virus capsid to develop a genomic treatment for a central nervous system disease, Sangamo announced on April 3.
